SLC5A2 and diabetic kidney disease: The phenotypic differences between our study and the previous study using Sglt2-knockout mice suggest the presence of other factors as well as SGLT2 inhibitor treatment that attenuate diabetic nephropathy in c-MafΔTAM mice.